TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07802964: A Randomized, Double-blind, Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a Single Oral Dose of HRS-4139 in Healthy Participants

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,614,080

Rescue Site Savings

+$3,701,784

Unlock Full NCT07802964 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07802964 Rescue Dossier →